Avidity Biosciences Inc Ordinary Shares RNA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Avidity Biosciences to Participate in Upcoming Investor Conference
-
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Avidity Biosciences Joins Patient and Advocacy Communities in Raising Awareness During National Muscular Dystrophy Awareness Month
-
Avidity Biosciences to Participate in Upcoming Investor Conferences
-
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Avidity Biosciences Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
-
Avidity Biosciences Announces Pricing of Upsized Public Offering of Common Stock
-
Avidity Biosciences Announces Proposed Public Offering of Common Stock
Trading Information
- Previous Close Price
- $42.17
- Day Range
- $41.58–43.18
- 52-Week Range
- $4.83–48.80
- Bid/Ask
- $42.32 / $42.33
- Market Cap
- $5.00 Bil
- Volume/Avg
- 911,904 / 1.5 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 343.82
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Avidity Biosciences Inc is a biotechnology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Its product, AOC 1001, is designed to treat a rare monogenic muscle disease.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 253
Comparables
Valuation
|
Metric
|
RNA
|
FULC
|
RCKT
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 3.79 | 0.86 | 4.37 |
Price/Sales | 343.82 | 2.90 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
RNA
FULC
RCKT
Financial Strength
|
Metric
|
RNA
|
FULC
|
RCKT
|
|---|---|---|---|
Quick Ratio | 15.61 | 21.84 | 7.42 |
Current Ratio | 15.78 | 22.07 | 7.79 |
Interest Coverage | — | — | −143.43 |
Quick Ratio
RNA
FULC
RCKT
Profitability
|
Metric
|
RNA
|
FULC
|
RCKT
|
|---|---|---|---|
Return on Assets (Normalized) | −25.50% | −1.76% | −41.09% |
Return on Equity (Normalized) | −28.88% | −1.91% | −46.72% |
Return on Invested Capital (Normalized) | −33.01% | −1.83% | −47.69% |
Return on Assets
RNA
FULC
RCKT
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Wtqldpdx | Kps | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Vnxttwwq | Jwlpsn | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Gjhxyfzg | Xhrzzw | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Gftgxskcm | Vcbrx | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Nxhykcg | Lrhm | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Kpmqhhwc | Xjk | $28.1 Bil | |||
| Moderna Inc
MRNA
| Rxgdcxqk | Wznwf | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Jthhlnty | Rxgn | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Jkmpshd | Nxscw | $13.4 Bil | |||
| Incyte Corp
INCY
| Gvbjlhjl | Jjccwrj | $12.7 Bil |
United States